6338-55-2

Usage

Uses

Used in Diagnostic Applications:
2-[2-(2-AMINOETHOXY)ETHOXY]ETHANOL is used as a blocking agent for preventing nonspecific adsorption of analytes in diagnostic assays such as ELISA. The application reason is to enhance the specificity and accuracy of the assays by reducing the adsorption of IgG on carboxylic-terminated surfaces.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-[2-(2-AMINOETHOXY)ETHOXY]ETHANOL is used as a stabilizing agent for protein formulations. The application reason is to improve the stability and shelf life of protein-based drugs by minimizing their interaction with surfaces and reducing the risk of aggregation.
Used in Research and Development:
2-[2-(2-AMINOETHOXY)ETHOXY]ETHANOL is used as a research tool for studying protein-surface interactions and developing novel protein coupling techniques. The application reason is to provide a means to investigate the underlying mechanisms of nonspecific adsorption and to design more effective strategies for minimizing it in various experimental setups.
Used in Surface Modification:
In the field of surface modification, 2-[2-(2-AMINOETHOXY)ETHOXY]ETHANOL is used as a coating agent to create surfaces with reduced protein adsorption properties. The application reason is to develop surfaces that are less prone to fouling and biocompatibility issues, which can be beneficial in various applications such as medical devices, sensors, and lab-on-a-chip systems.

InChI:InChI=1/C6H15NO3/c7-1-3-9-5-6-10-4-2-8/h8H,1-7H2

Upstream product

• 92505-83-4 N-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethyl}-acetamide 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 75001-08-0 2-{2-[2-(2-hydroxyethoxy)ethoxy]ethyl}isoindole-1,3-dione 
• 86770-70-9 ((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)benzene 
• 7664-41-7 ammonia 
• 5197-62-6 2-[2-(chloroethoxy)ethoxy]ethanol 
• 55489-58-2 triethylene glycol monobenzyl ether 
• 77544-68-4 8-tosyloxy-3,6-dioxaoctanol 
• 57641-67-5 2-(2′-(2″-bromoethoxy)ethoxy)ethanol 
• 139115-92-7 tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate 
• 201037-95-8 2-(2-(2-(tert-butyl-dimethyl-silanyloxy)-ethoxy)-ethoxy)-ethanol 
• 105891-50-7 1-chloro-10-phenyl-3,6,9-trioxadecane 
• 1349193-22-1 8-dibenzylamino-3,6-dioxaoctan-1-ol 

Downstream Products

• 25743-12-8 3,6,12,15-tetraoxa-9-azaheptadecane-1,17-diol 
• 139115-92-7 tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate 
• 198063-15-9 5-(dimethylamino)-N-{2-[2-(2-hydroxyethoxy)ethoxy]ethyl}-1-naphthalenesulfonamide 
• 205535-92-8 2-[2-{2-(N-benzyloxycarbonyl)aminoethoxy}ethoxy]ethanol 
• 933046-48-1 {2-[2-(2-hydroxyethoxy)ethoxy]ethyl}carbamic acid 4-nitro-benzyl ester 
• 933046-49-2 methanesulfonic acid 2-{2-[2-(4-nitro-benzyloxycarbonylamino)ethoxy]ethoxy}ethyl ester 
• 933046-46-9 {2-[2-(2-piperazin-1-yl-ethoxy)ethoxy]ethoxy}-carbamic acid 4-nitro-benzyl ester 
• 933046-50-5 4-(2-{2-[2-(4-nitrobenzyloxycarbonylamino)ethoxy]ethoxy}ethyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 933046-91-4 C₂₉H₄₇N₉O₁₁ 
• 933046-94-7 C₃₁H₄₅N₉O₁₁S 

Relevant academic research and scientific papers

Cofactor-free detection of phosphatidylserine with cyclic peptides mimicking lactadherin

Cyclic peptides (cLacs) are designed to mimic the natural phosphatidylserine (PS) binding protein lactadherin. Unlike annexin V or its small molecule mimics, the cLac peptides selectively target PS-presenting membranes with no need for metal cofactors. We further show that a fluorophore-labeled cLac effectively stains early apoptotic cells. The small size and facile conjugation with a variety of imaging tracers make the cLac design promising for imaging cell death in vitro as well as in living organisms.

Self-Assembly and Molecular Recognition in Water: Tubular Stacking and Guest-Templated Discrete Assembly of Water-Soluble, Shape-Persistent Macrocycles

Supramolecular chemistry in aqueous media is an area with great fundamental and practical significance. To examine the role of multiple noncovalent interactions in controlled assembling and binding behavior in water, the self-association of five water-soluble hexakis(m-phenylene ethynylene) (m-PE) macrocycles, along with the molecular recognition behavior of the resultant assemblies, is investigated with UV-vis, fluorescence, CD, and NMR spectroscopy, mass spectrometry, and computational studies. In contrast to their different extents of self-aggregation in organic solvents, all five macrocycles remain aggregated in water at concentrations down to the micromolar (μM) range. CD spectroscopy reveals that 1-F6 and 1-H6, two macrocycles carrying chiral side chains and capable of H-bonded self-association, assemble into tubular stacks. The tubular stacks serve as supramolecular hosts in water, as exemplified by the interaction of macrocycles 1-H6 and 2-H6 and guests G1 through G4, each having a rod-like oligo(p-phenylene ethynylene) (p-PE) segment flanked by two hydrophilic chains. Fluorescence and 1H NMR spectroscopy revealed the formation of kinetically stable, discrete assemblies upon mixing 2-H6 and a guest. The binding stoichiometry, determined with fluorescence, 1H NMR, and ESI-MS, reveals that the discrete assemblies are novel pseudorotaxanes, each containing a pair of identical guest molecules encased by a tubular stack. The two guest molecules define the number of macrocyclic molecules that comprise the host, which curbs the "infinite" stack growth, resulting in a tubular stack with a cylindrical pore tailoring the length of the p-PE segment of the bound guests. Each complex is stabilized by the action of multiple noncovalent forces including aromatic stacking, side-chain H-bonding, and van der Waals interactions. Thus, the interplay of multiple noncovalent forces aligns the molecules of macrocycles 1 and 2 into tubular stacks with cylindrical inner pores that, upon binding rod-like guests, lead to tight, discrete, and well-ordered tubular assemblies that are unprecedented in water.

MERTK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

The effect of monosaccharides on self-assembly of benzenetricarboxamides

The interaction between monosaccharides exhibits an important role in the assembly of monosaccharide-containing molecules. In this work, three common monosaccharides, glucose, galactose and mannose, are employed to investigate the effect of monosaccharide on the self-assembly of benzenetricarboxamide (BTA) core-containing molecules. In the presence of monosaccharides, three benzenetricarboxamide derivatives aggregate into different ordered structures. When alanine linkers are introduced to these molecules between the core and the monosacchride, morphologies of three types of monosaccharide BTAs turned to disordered, meanwhile their structures become similar with the increase of the length of alanine linkers, indicating the disappearance of the monosaccharide effects.

Multiple arms polymerization target anticancer conjugate

Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.

Targeting multi-arm conjugate (by machine translation)

The present invention discloses a multi-arm, by the water-soluble polymer modified folic acid receptor targeted drug conjugates and salts thereof. The drug conjugate has the following structural formula: The invention is a multi-arm polymer modified targeting anticancer conjugate, wherein the water-soluble polymer may be modified to enhance the water solubility of the conjugate, thereby increasing the drug loading. In the invention of targeting molecules for folic acid, folic acid as a targeting molecule, folic acid receptor expressing abundant active targeting of tumor cells, play a better anti-tumor efficacy, increase target, and thus make the concentration of the conjugate in the targeted tissue more high. (by machine translation)

SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES

The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymallytransformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

NIRF turn-on nanoparticles based on the tumor microenvironment for monitoring intracellular protein delivery

A dual responsive NIRF turn-on protein delivery system incorporating an NIRF turn-on probe and protein into one single nanoparticle has been constructed. It can be taken up efficiently by A549 cells, where protein release and NIRF recovery happen simultaneously in response to low pH and excessive H2O2. This work provides a novel system for monitoring intracellular protein delivery.

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF

The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.